Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 332

1.

Clinical Impact of Perioperative Oral/Dental Care on Cancer Surgery Outcomes.

Aoyama T, Tamagawa A.

Anticancer Res. 2019 Jun;39(6):2711-2714. doi: 10.21873/anticanres.13396. Review.

PMID:
31177105
2.

Clinical and Therapeutic Implications of Cancer Stem Cells.

Clarke MF.

N Engl J Med. 2019 Jun 6;380(23):2237-2245. doi: 10.1056/NEJMra1804280. Review. No abstract available.

PMID:
31167052
3.

The nephrotoxicity of new immunotherapies.

Sury K, Perazella MA.

Expert Rev Clin Pharmacol. 2019 Jun;12(6):513-521. doi: 10.1080/17512433.2019.1613888. Epub 2019 May 8. Review.

PMID:
31035801
4.

Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer.

Gonzalez-Avila G, Sommer B, Mendoza-Posada DA, Ramos C, Garcia-Hernandez AA, Falfan-Valencia R.

Crit Rev Oncol Hematol. 2019 May;137:57-83. doi: 10.1016/j.critrevonc.2019.02.010. Epub 2019 Mar 3. Review. Erratum in: Crit Rev Oncol Hematol. 2019 Jun;138:172.

5.

Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment.

Nayak R, Meerovich I, Dash AK.

AAPS PharmSciTech. 2019 Apr 9;20(4):160. doi: 10.1208/s12249-019-1367-2. Review.

PMID:
30968269
6.

The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer.

Cai J, Qi Q, Qian X, Han J, Zhu X, Zhang Q, Xia R.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1377-1385. doi: 10.1007/s00432-019-02879-2. Epub 2019 Apr 8. Review.

PMID:
30963235
7.

Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.

Sanchez-Correa B, Lopez-Sejas N, Duran E, Labella F, Alonso C, Solana R, Tarazona R.

Cancer Immunol Immunother. 2019 May;68(5):861-870. doi: 10.1007/s00262-019-02336-6. Epub 2019 Apr 5. Review.

PMID:
30953117
8.

Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers.

Nussinov R, Jang H, Tsai CJ, Cheng F.

PLoS Comput Biol. 2019 Mar 28;15(3):e1006658. doi: 10.1371/journal.pcbi.1006658. eCollection 2019 Mar. Review. Erratum in: PLoS Comput Biol. 2019 Jun 12;15(6):e1007114.

9.

Development of Cancer Immunotherapy Targeting the PD-1 Pathway.

Kamimura N, Wolf AM, Iwai Y.

J Nippon Med Sch. 2019;86(1):10-14. doi: 10.1272/jnms.JNMS.2019_86-2. Review.

10.

Controlling metastatic cancer: the role of phytochemicals in cell signaling.

Kapinova A, Kubatka P, Liskova A, Baranenko D, Kruzliak P, Matta M, Büsselberg D, Malicherova B, Zulli A, Kwon TK, Jezkova E, Blahutova D, Zubor P, Danko J.

J Cancer Res Clin Oncol. 2019 May;145(5):1087-1109. doi: 10.1007/s00432-019-02892-5. Epub 2019 Mar 22. Review.

PMID:
30903319
11.

Memory NK Cell Features Exploitable in Anticancer Immunotherapy.

Capuano C, Pighi C, Battella S, Santoni A, Palmieri G, Galandrini R.

J Immunol Res. 2019 Feb 6;2019:8795673. doi: 10.1155/2019/8795673. eCollection 2019. Review.

12.

Cancer targeting peptides.

Kalmouni M, Al-Hosani S, Magzoub M.

Cell Mol Life Sci. 2019 Jun;76(11):2171-2183. doi: 10.1007/s00018-019-03061-0. Epub 2019 Mar 15. Review.

PMID:
30877335
13.

Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases.

Bachmann N, Leiser D, Ermis E, Vulcu S, Schucht P, Raabe A, Aebersold DM, Herrmann E.

Radiat Oncol. 2019 Mar 14;14(1):45. doi: 10.1186/s13014-019-1252-x.

14.

Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.

Chen S, Song Z, Zhang A.

Curr Top Med Chem. 2019;19(3):180-185. doi: 10.2174/1568026619666190308131805. Review.

PMID:
30854972
15.

Afterword.

Gayet B, Fuks D.

Surg Oncol Clin N Am. 2019 Apr;28(2):333-335. doi: 10.1016/j.soc.2018.11.013. Epub 2019 Jan 7. Review.

PMID:
30851833
16.

Rectus Sheath Block (RSB) Analgesia Could Enhance Significantly the Patient Satisfaction Following Midline Laparotomy in Benign Disease and in Cancer: A Prospective Study With Special Reference to Nitrosative Stress Marker Nitrotyrosine (NT) Plasma Concentrations.

Kuosmanen V, Saimanen I, Rahkola D, Kärkkäinen J, Selander T, Purdy M, Kokki H, Kokki M, Eskelinen M.

Anticancer Res. 2019 Mar;39(3):1383-1389. doi: 10.21873/anticanres.13252.

PMID:
30842172
17.

Engineering advanced cancer therapies with synthetic biology.

Wu MR, Jusiak B, Lu TK.

Nat Rev Cancer. 2019 Apr;19(4):187-195. doi: 10.1038/s41568-019-0121-0. Review.

PMID:
30837696
18.

Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.

Chang X, Lu X, Guo J, Teng GJ.

Cancer Treat Rev. 2019 Mar;74:49-60. doi: 10.1016/j.ctrv.2018.08.006. Epub 2018 Aug 20. Review.

PMID:
30831375
19.

Novel insights into the role of aptamers in the fight against cancer.

Maimaitiyiming Y, Hong F, Yang C, Naranmandura H.

J Cancer Res Clin Oncol. 2019 Apr;145(4):797-810. doi: 10.1007/s00432-019-02882-7. Epub 2019 Mar 4. Review.

PMID:
30830295
20.

Exosomes in the tumor microenvironment as mediators of cancer therapy resistance.

Li I, Nabet BY.

Mol Cancer. 2019 Mar 1;18(1):32. doi: 10.1186/s12943-019-0975-5. Review.

Supplemental Content

Loading ...
Support Center